Ken Griffin Catalent, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$53.58 - $57.02 $26,790 - $28,510	500 Added 1.21%	41,800 $2.35 Million
Q1 2024 May 15, 2024	SELL	$42.56 - $59.82 $4.58 Million - $6.44 Million	-107,600 Reduced 72.26%	41,300 $2.33 Million
Q4 2023 Feb 14, 2024	SELL	$32.18 - $46.57 $54,706 - $79,169	-1,700 Reduced 1.13%	148,900 $6.69 Million
Q3 2023 Nov 14, 2023	BUY	$44.2 - $50.2 $1.61 Million - $1.83 Million	36,400 Added 31.87%	150,600 $6.86 Million
Q2 2023 Aug 14, 2023	SELL	$31.86 - $67.26 $1.85 Million - $3.91 Million	-58,100 Reduced 33.72%	114,200 $4.95 Million
Q1 2023 May 15, 2023	BUY	$45.44 - $74.26 $6.19 Million - $10.1 Million	136,300 Added 378.61%	172,300 $11.3 Million
Q4 2022 Feb 14, 2023	SELL	$41.39 - $81.0 $7.62 Million - $14.9 Million	-184,100 Reduced 83.64%	36,000 $1.62 Million
Q3 2022 Nov 14, 2022	BUY	$72.36 - $113.1 $14.8 Million - $23.1 Million	203,900 Added 1258.64%	220,100 $15.9 Million

496

165M

274K

1.03M

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $10.6B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.